Sahar M A Hassanein1, Shaymaa M Deifallah2, Hend A Bastawy3. 1. Pediatric Department, Pediatric Neuropsychiatry Unit, Faculty of Medicine, Ain Shams University, Abbassia Square, P.O.Box 11381, Cairo, Egypt. saharhassanein@med.asu.edu.eg. 2. Pediatric Department, Pediatric Neuropsychiatry Unit, Faculty of Medicine, Ain Shams University, Abbassia Square, P.O.Box 11381, Cairo, Egypt. 3. Ministry of Health, Cairo, Egypt.
Abstract
BACKGROUND: Constipation is a common problem in children with spastic cerebral palsy (sCP) with a prevalence that reaches 75%. We hypothesized that treating constipation in those children will improve their health and shorten time spent in daily care. Our aim was to evaluate the efficacy and safety of oral magnesium sulfate for treating chronic constipation in children with sCP. METHODS: A prospective, double-blinded randomized control trial was carried out involving 100 children aged 2-12 years with sCP (level III-V of the Gross Motor Functional Classification system) and chronic constipation. They were followed up in the Pediatric neurology clinic, Children's hospital, Ain Shams University, May 2017- January 2019. The intervention group (O-Mg) received oral magnesium sulfate 1 mL/kg/day daily for 1 month compared to the placebo. Outcome measures were constipation improvement and decrease in bowel evacuation time after 1 month. RESULTS: Initially, weekly bowel movements, constipation scores and stool consistency were comparable in both groups. After 1 month of regular administration of oral magnesium sulfate, the constipation score, stool frequency and consistency improved compared to the placebo group (P < 0.001). Effective safe treatment was achieved in 31 (68%) and 4 (9.5%) patients in the O-Mg and placebo groups, respectively (RR, 2.95; 95% CI 2.0-4.5) (P < 0.001). Painful bowel evacuation attempts spent by mothers decreased from 25 (55.6%) of the cases initially to 10 (22%) cases after one month in the O-Mg group (P = 0.001). In contrast, in the placebo group, the decrease went from 21 (50%) cases initially to 18 (42.9%) after 1 month and was not significant (P = 0.5). CONCLUSIONS:Oral magnesium sulfate seems effective in alleviating chronic constipation and pain experience in children with sCP. Consequently, saving maternal time spent in daily bowel evacuation attempts.
RCT Entities:
BACKGROUND:Constipation is a common problem in children with spastic cerebral palsy (sCP) with a prevalence that reaches 75%. We hypothesized that treating constipation in those children will improve their health and shorten time spent in daily care. Our aim was to evaluate the efficacy and safety of oral magnesium sulfate for treating chronic constipation in children with sCP. METHODS: A prospective, double-blinded randomized control trial was carried out involving 100 children aged 2-12 years with sCP (level III-V of the Gross Motor Functional Classification system) and chronic constipation. They were followed up in the Pediatric neurology clinic, Children's hospital, Ain Shams University, May 2017- January 2019. The intervention group (O-Mg) received oral magnesium sulfate 1 mL/kg/day daily for 1 month compared to the placebo. Outcome measures were constipation improvement and decrease in bowel evacuation time after 1 month. RESULTS: Initially, weekly bowel movements, constipation scores and stool consistency were comparable in both groups. After 1 month of regular administration of oral magnesium sulfate, the constipation score, stool frequency and consistency improved compared to the placebo group (P < 0.001). Effective safe treatment was achieved in 31 (68%) and 4 (9.5%) patients in the O-Mg and placebo groups, respectively (RR, 2.95; 95% CI 2.0-4.5) (P < 0.001). Painful bowel evacuation attempts spent by mothers decreased from 25 (55.6%) of the cases initially to 10 (22%) cases after one month in the O-Mg group (P = 0.001). In contrast, in the placebo group, the decrease went from 21 (50%) cases initially to 18 (42.9%) after 1 month and was not significant (P = 0.5). CONCLUSIONS: Oral magnesium sulfate seems effective in alleviating chronic constipation and pain experience in children with sCP. Consequently, saving maternal time spent in daily bowel evacuation attempts.
Authors: K Tanaka; Y Miyake; S Sasaki; Y Ohya; S Miyamoto; I Matsunaga; T Yoshida; Y Hirota; H Oda Journal: Magnes Res Date: 2006-12 Impact factor: 1.115
Authors: Hamdy N El-Tallawy; Wafaa Ma Farghaly; Ghaydaa A Shehata; Tarek A Rageh; Nabil A Metwally; Reda Badry; Mohamed Am Sayed; Mohamed Abd El Hamed; Ahmed Abd-Elwarth; Mahmoud R Kandil Journal: Neuropsychiatr Dis Treat Date: 2014-07-08 Impact factor: 2.570
Authors: Mohammad Hadi Imanieh; Mohammad Reza Golpayegan; Mostafa Sedighi; Kamal Ahmadi; Abbas Aghaie; Seyed Mohsen Dehghani; Gholamreza Yousefi Journal: Prz Gastroenterol Date: 2019-05-08